19026743	207	Zhao WQ	Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease.	Biochimica et biophysica acta	2009	56
26367797	338	UK10K Consortium.	The UK10K project identifies rare variants in health and disease.	Nature	2015	135
14729357	348	Anderson DH	Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration.	Experimental eye research	2004	85
24559670	348	Kanekiyo T	ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?	Neuron	2014	66
25988462	348	Jansen WJ	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.	JAMA	2015	73
10978169	351	Walsh DM	The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain.	Biochemistry	2000	115
16645451	351	Xie Z	The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid beta protein levels.	Anesthesiology	2006	73
17360908	351	Shankar GM	Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway.	The Journal of neuroscience 	2007	440
18359102	351	Selkoe DJ	Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.	Behavioural brain research	2008	303
18548070	351	Kukar TL	Substrate-targeting gamma-secretase modulators.	Nature	2008	104
22017494	351	Rosen RF	Exogenous seeding of cerebral β-amyloid deposition in βAPP-transgenic rats.	Journal of neurochemistry	2012	36
25253695	351	Benilova I	The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation.	The Journal of biological chemistry	2014	27
23111421	1066	Lewis JP	The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.	Pharmacogenetics and genomics	2013	27
10075921	1080	Meacham GC	The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis.	The EMBO journal	1999	106
19181854	1080	Rath A	Detergent binding explains anomalous SDS-PAGE migration of membrane proteins.	Proceedings of the National Academy of Sciences of the United States of America	2009	176
19944699	1080	Lewis HA	Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry.	Journal of molecular biology	2010	50
22179788	1191	Narayan P	The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β(1-40) peptide.	Nature structural and molecular biology	2011	62
15173060	1401	Landmesser U	Endothelial function: a critical determinant in atherosclerosis?	Circulation	2004	114
19011614	1401	Lu J	Structural recognition and functional activation of FcgammaR by innate pentraxins.	Nature	2008	67
22819432	1401	Ballantyne CM	Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).	The American journal of cardiology	2012	35
16210548	1410	Chen Q	Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake.	Circulation research	2005	66
20843828	1410	Vos MJ	HSPB7 is the most potent polyQ aggregation suppressor within the HSPB family of molecular chaperones.	Human molecular genetics	2010	43
22683760	1410	Wettstein G	Small heat shock proteins and the cytoskeleton: an essential interplay for cell integrity?	The international journal of biochemistry and cell biology	2012	35
24942756	1437	Lutz ER	Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.	Cancer immunology research	2014	63
19414633	1544	Mega JL	Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.	Circulation	2009	70
19812348	1544	Kazui M	Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.	Drug metabolism and disposition	2010	93
18482659	1557	Trenk D	Cytochrome P450 2C19 681G&amp;gt;A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.	Journal of the American College of Cardiology	2008	75
19106083	1557	Simon T	Genetic determinants of response to clopidogrel and cardiovascular events.	The New England journal of medicine	2009	232
19106084	1557	Mega JL	Cytochrome p-450 polymorphisms and response to clopidogrel.	The New England journal of medicine	2009	286
19108880	1557	Collet JP	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.	Lancet	2009	126
19193675	1557	Sibbing D	Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.	European heart journal	2009	56
19706858	1557	Shuldiner AR	Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.	JAMA	2009	239
20083681	1557	Sibbing D	Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.	Circulation	2010	82
20620727	1557	Hulot JS	Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.	Journal of the American College of Cardiology	2010	56
20801494	1557	Mega JL	Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.	Lancet	2010	74
20801498	1557	Wallentin L	Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.	Lancet	2010	83
20978260	1557	Mega JL	Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.	JAMA	2010	145
20979470	1557	Paré G	Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.	The New England journal of medicine	2010	87
22088980	1557	Mega JL	Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.	JAMA	2011	51
22190063	1557	Delaney JT	Predicting clopidogrel response using DNA samples linked to an electronic health record.	Clinical pharmacology and therapeutics	2012	40
22203539	1557	Holmes MV	CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.	JAMA	2011	84
22464343	1557	Roberts JD	Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.	Lancet	2012	52
22588608	1557	Pulley JM	Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project.	Clinical pharmacology and therapeutics	2012	119
23698643	1557	Scott SA	Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.	Clinical pharmacology and therapeutics	2013	96
24616408	1557	Shuldiner AR	Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program.	American journal of medical genetics. Part C, Seminars in medical genetics	2014	24
15943797	1674	Sun Y	The small heat shock proteins and their role in human disease.	The FEBS journal	2005	68
12796140	1844	Gurbel PA	Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.	Circulation	2003	143
18458324	2056	Tong Z	Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications.	Proceedings of the National Academy of Sciences of the United States of America	2008	53
25611051	2056	Tefferi A	Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.	American journal of hematology	2015	22
2147038	2147	Bleasdale JE	Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils.	The Journal of pharmacology and experimental therapeutics	1990	148
12588269	2147	Lincoff AM	Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.	JAMA	2003	91
17950801	2147	Ezekowitz MD	Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).	The American journal of cardiology	2007	56
19652875	2147	Jennings LK	Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.	Thrombosis and haemostasis	2009	60
21551462	2147	Oldgren J	Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.	European heart journal	2011	47
22077816	2147	Tricoci P	Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.	The New England journal of medicine	2012	84
22443427	2147	Morrow DA	Vorapaxar in the secondary prevention of atherothrombotic events.	The New England journal of medicine	2012	90
10079109	2149	Kahn ML	Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.	The Journal of clinical investigation	1999	123
24211234	2187	Davies AM	Structural determinants of unique properties of human IgG4-Fc.	Journal of molecular biology	2014	24
9439492	2244	Ridker PM	Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.	Lancet	1998	137
20020753	2244	Lacerda SH	Interaction of gold nanoparticles with common human blood proteins.	ACS nano	2010	65
24335500	2244	Cines DB	Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin.	Blood	2014	23
11731781	2247	Zhang SC	In vitro differentiation of transplantable neural precursors from human embryonic stem cells.	Nature biotechnology	2001	367
19842915	2247	Solchaga LA	Fibroblast growth factor-2 enhances proliferation and delays loss of chondrogenic potential in human adult bone-marrow-derived mesenchymal stem cells.	Tissue engineering. Part A	2010	50
21494607	2247	Burridge PW	A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability.	PloS one	2011	120
9111868	2335	Naor D	CD44: structure, function, and association with the malignant process.	Advances in cancer research	1997	183
18424525	2335	Valle J	UpaG, a new member of the trimeric autotransporter family of adhesins in uropathogenic Escherichia coli.	Journal of bacteriology	2008	54
21408206	2521	Huang C	FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration.	PLoS genetics	2011	64
26317470	2521	Patel A	A Liquid-to-Solid Phase Transition of the ALS Protein FUS Accelerated by Disease Mutation.	Cell	2015	108
9302293	3064	DiFiglia M	Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.	Science	1997	565
11406612	3064	Sittler A	Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease.	Human molecular genetics	2001	96
12747895	3064	Bates G	Huntingtin aggregation and toxicity in Huntington's disease.	Lancet	2003	103
14978262	3064	Lee WC	Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease.	Proceedings of the National Academy of Sciences of the United States of America	2004	95
15340079	3064	Trushina E	Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro.	Molecular and cellular biology	2004	138
16893904	3064	Ehrnhoefer DE	Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models.	Human molecular genetics	2006	77
16980959	3064	Tam S	The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions.	Nature cell biology	2006	108
17118264	3064	Williams A	Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications.	Current topics in developmental biology	2006	104
18756251	3064	Kaganovich D	Misfolded proteins partition between two distinct quality control compartments.	Nature	2008	275
19710014	3064	Aiken CT	Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity.	The Journal of biological chemistry	2009	46
21571086	3064	Moreno-Gonzalez I	Misfolded protein aggregates: mechanisms, structures and potential for disease transmission.	Seminars in cell and developmental biology	2011	42
22735540	3064	Pieri L	Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to the cells.	Biophysical journal	2012	52
25437566	3064	Brehme M	A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease.	Cell reports	2014	50
27188817	3064	Bates GP	Huntington disease.	Nature reviews. Disease primers	2015	36
22693999	3135	Valleix S	Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin.	The New England journal of medicine	2012	32
16076838	3297	Westerheide SD	Heat shock response modulators as therapeutic tools for diseases of protein conformation.	The Journal of biological chemistry	2005	133
19546513	3297	Calderwood SK	The shock of aging: molecular chaperones and the heat shock response in longevity and aging--a mini-review.	Gerontology	2009	76
21451522	3297	Alavez S	Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan.	Nature	2011	87
14740253	3308	Wegele H	Hsp70 and Hsp90--a relay team for protein folding.	Reviews of physiology, biochemistry and pharmacology	2004	133
19393652	3308	Broadley SA	The role of molecular chaperones in human misfolding diseases.	FEBS letters	2009	59
22449631	3308	Garrido C	The small heat shock proteins family: the long forgotten chaperones.	The international journal of biochemistry and cell biology	2012	44
26300264	3308	Gao X	Human Hsp70 Disaggregase Reverses Parkinson's-Linked α-Synuclein Amyloid Fibrils.	Molecular cell	2015	34
26865365	3308	Radons J	The human HSP70 family of chaperones: where do we stand?	Cell stress and chaperones	2016	15
2195544	3375	Westermark P	Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation.	Proceedings of the National Academy of Sciences of the United States of America	1990	148
18442979	3375	Apostolidou M	Structure of alpha-helical membrane-bound human islet amyloid polypeptide and its implications for membrane-mediated misfolding.	The Journal of biological chemistry	2008	62
19208933	3375	Abedini A	A role for helical intermediates in amyloid formation by natively unfolded polypeptides?	Physical biology	2009	57
19244249	3375	Patil SM	Dynamic alpha-helix structure of micelle-bound human amylin.	The Journal of biological chemistry	2009	49
19346479	3375	Shim SH	Two-dimensional IR spectroscopy and isotope labeling defines the pathway of amyloid formation with residue-specific resolution.	Proceedings of the National Academy of Sciences of the United States of America	2009	86
21723249	3375	Nanga RP	Structure and membrane orientation of IAPP in its natively amidated form at physiological pH in a membrane environment.	Biochimica et biophysica acta	2011	42
21818468	3375	DeToma AS	Misfolded proteins in Alzheimer's disease and type II diabetes.	Chemical Society reviews	2012	49
21916515	3375	Wang L	2DIR spectroscopy of human amylin fibrils reflects stable β-sheet structure.	Journal of the American Chemical Society	2011	35
21942864	3375	Brender JR	Membrane disruption and early events in the aggregation of the diabetes related peptide IAPP from a molecular perspective.	Accounts of chemical research	2012	63
23611538	3375	Palhano FL	Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils.	Journal of the American Chemical Society	2013	37
24218609	3375	Buchanan LE	Mechanism of IAPP amyloid fibril formation involves an intermediate with a transient β-sheet.	Proceedings of the National Academy of Sciences of the United States of America	2013	36
25515893	3375	Young LM	Screening and classifying small-molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry.	Nature chemistry	2015	22
3086451	3383	Dustin ML	Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1).	Journal of immunology	1986	365
3525675	3383	Rothlein R	A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1.	Journal of immunology	1986	225
9347951	3383	Newbold C	Receptor-specific adhesion and clinical disease in Plasmodium falciparum.	The American journal of tropical medicine and hygiene	1997	117
11854119	3383	Ziccardi P	Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year.	Circulation	2002	131
16429128	3383	Millán J	Lymphocyte transcellular migration occurs through recruitment of endothelial ICAM-1 to caveola- and F-actin-rich domains.	Nature cell biology	2006	104
16973825	3383	Csiszar A	Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: role of NF-kappaB inhibition.	American journal of physiology. Heart and circulatory physiology	2006	88
21408027	3569	Bao B	Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.	PloS one	2011	71
15292279	3630	Hull RL	Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes.	The Journal of clinical endocrinology and metabolism	2004	122
15564314	3630	Gershengorn MC	Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells.	Science	2004	100
10617772	3949	Schroepfer GJ Jr	Oxysterols: modulators of cholesterol metabolism and other processes.	Physiological reviews	2000	112
20739751	3949	Rashid ST	Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells.	The Journal of clinical investigation	2010	160
9039909	4069	Booth DR	Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis.	Nature	1997	172
15361882	4069	Fernandez-Escamilla AM	Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins.	Nature biotechnology	2004	313
16807328	4137	Dickey CA	Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3-cleaved tau species.	The Journal of neuroscience 	2006	78
17683088	4137	Goris A	Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease.	Annals of neurology	2007	64
18199773	4137	Mocanu MM	The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.	The Journal of neuroscience 	2008	70
18798283	4137	LaPointe NE	The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity.	Journal of neuroscience research	2009	78
21427723	4137	Cohen TJ	The acetylation of tau inhibits its function and promotes pathological tau aggregation.	Nature communications	2011	96
22556362	4137	Coppola G	Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases.	Human molecular genetics	2012	54
23684085	4137	Spillantini MG	Tau pathology and neurodegeneration.	The Lancet. Neurology	2013	121
25393609	4137	Sokolow S	Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.	Journal of neurochemistry	2015	19
22113611	4287	Koch P	Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease.	Nature	2011	74
9874808	4512	McAdam BF	Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.	Proceedings of the National Academy of Sciences of the United States of America	1999	164
25822790	5028	Zhang D	Two disparate ligand-binding sites in the human P2Y1 receptor.	Nature	2015	29
17296677	5054	Cumashi A	A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds.	Glycobiology	2007	98
20522742	5265	Hidvegi T	An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis.	Science	2010	157
15313629	5621	Linding R	A comparative study of the relationship between protein structure and beta-aggregation in globular and intrinsically disordered proteins.	Journal of molecular biology	2004	78
19789378	5621	Aguzzi A	Prions: protein aggregation and infectious diseases.	Physiological reviews	2009	118
22057275	5621	Saman S	Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease.	The Journal of biological chemistry	2012	167
26324905	5621	Prusiner SB	Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism.	Proceedings of the National Academy of Sciences of the United States of America	2015	63
26791950	5621	Minikel EV	Quantifying prion disease penetrance using large population control cohorts.	Science translational medicine	2016	24
17553989	5663	Klunk WE	Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.	The Journal of neuroscience 	2007	111
17962197	5663	Page RM	Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation.	The Journal of biological chemistry	2008	53
18300294	5663	Tomiyama T	A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia.	Annals of neurology	2008	104
25307057	5663	Choi SH	A three-dimensional human neural cell culture model of Alzheimer's disease.	Nature	2014	111
26481686	5663	Szaruga M	Qualitative changes in human γ-secretase underlie familial Alzheimer's disease.	The Journal of experimental medicine	2015	16
11752357	5742	Catella-Lawson F	Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.	The New England journal of medicine	2001	122
22722194	5742	Lounkine E	Large-scale prediction and testing of drug activity on side-effect targets.	Nature	2012	157
9546347	6620	Baba M	Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.	The American journal of pathology	1998	255
9197268	6622	Polymeropoulos MH	Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.	Science	1997	1344
10391881	6622	Wood SJ	alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease.	The Journal of biological chemistry	1999	122
11152691	6622	Uversky VN	Evidence for a partially folded intermediate in alpha-synuclein fibril formation.	The Journal of biological chemistry	2001	189
11553618	6622	Uversky VN	Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure.	The Journal of biological chemistry	2001	171
11560511	6622	Li J	Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.	Biochemistry	2001	102
11572944	6622	Masliah E	beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2001	110
12084935	6622	Lee MK	Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --&amp;gt; Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.	Proceedings of the National Academy of Sciences of the United States of America	2002	148
12122208	6622	Lo Bianco C	alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.	Proceedings of the National Academy of Sciences of the United States of America	2002	112
12177198	6622	Sherer TB	An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.	The Journal of neuroscience 	2002	116
12217698	6622	Hoyer W	Dependence of alpha-synuclein aggregate morphology on solution conditions.	Journal of molecular biology	2002	91
15845543	6622	Shin Y	The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways.	The Journal of biological chemistry	2005	81
16507759	6622	El-Agnaf OM	Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.	FASEB journal 	2006	133
17088319	6622	Marsh JA	Sensitivity of secondary structure propensities to sequence differences between alpha- and gamma-synuclein: implications for fibrillation.	Protein science 	2006	167
17254549	6622	Hoozemans JJ	Activation of the unfolded protein response in Parkinson's disease.	Biochemical and biophysical research communications	2007	87
18511942	6622	Ehrnhoefer DE	EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers.	Nature structural and molecular biology	2008	201
18704197	6622	Lo Bianco C	Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease.	The Journal of clinical investigation	2008	60
18769546	6622	Tsigelny IF	Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.	PloS one	2008	69
19686384	6622	Danzer KM	Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology.	Journal of neurochemistry	2009	71
19745811	6622	Karpinar DP	Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models.	The EMBO journal	2009	94
19892735	6622	Luk KC	Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells.	Proceedings of the National Academy of Sciences of the United States of America	2009	193
20071342	6622	Lee HJ	Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies.	The Journal of biological chemistry	2010	170
20203178	6622	Paleologou KE	Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions.	The Journal of neuroscience 	2010	68
20696318	6622	Oueslati A	Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.	Progress in brain research	2010	67
21613474	6622	Waxman EA	Induction of intracellular tau aggregation is promoted by α-synuclein seeds and provides novel insights into the hyperphosphorylation of tau.	The Journal of neuroscience 	2011	40
21700325	6622	Mazzulli JR	Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.	Cell	2011	216
21766334	6622	Shannon KM	Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.	Movement disorders 	2012	52
22737239	6622	Angot E	Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo.	PloS one	2012	46
22744791	6622	Ebrahimi-Fakhari D	Protein degradation pathways in Parkinson's disease: curse or blessing.	Acta neuropathologica	2012	33
25676491	6622	Sengupta U	Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.	Biological psychiatry	2015	20
26341711	6622	Petrucci S	Phenotypic spectrum of alpha-synuclein mutations: New insights from patients and cellular models.	Parkinsonism and related disorders	2016	13
26446103	6622	Uchihara T	Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.	Acta neuropathologica	2016	17
26564470	6622	Deas E	Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease.	Antioxidants and redox signaling	2016	16
26808899	6622	Theillet FX	Structural disorder of monomeric α-synuclein persists in mammalian cells.	Nature	2016	37
15326189	6647	Arnesano F	The unusually stable quaternary structure of human Cu,Zn-superoxide dismutase 1 is controlled by both metal occupancy and disulfide status.	The Journal of biological chemistry	2004	73
15758154	6647	Vijayvergiya C	Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice.	The Journal of neuroscience 	2005	67
17592131	6647	Banci L	Metal-free superoxide dismutase forms soluble oligomers under physiological conditions: a possible general mechanism for familial ALS.	Proceedings of the National Academy of Sciences of the United States of America	2007	77
18282652	6647	Turner BJ	Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS.	Progress in neurobiology	2008	144
18666828	6647	Wang Q	Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival.	PLoS biology	2008	53
19271992	6647	Chattopadhyay M	Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS.	Antioxidants and redox signaling	2009	45
19299510	6647	Wilcox KC	Modifications of superoxide dismutase (SOD1) in human erythrocytes: a possible role in amyotrophic lateral sclerosis.	The Journal of biological chemistry	2009	47
19483195	6647	Prudencio M	Variation in aggregation propensities among ALS-associated variants of SOD1: correlation to human disease.	Human molecular genetics	2009	61
19903735	6647	Walker AK	Protein disulphide isomerase protects against protein aggregation and is S-nitrosylated in amyotrophic lateral sclerosis.	Brain 	2010	44
20111867	6647	Kerman A	Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form.	Acta neuropathologica	2010	52
20644736	6647	Forsberg K	Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients.	PloS one	2010	86
22431618	6647	Brotherton TE	Localization of a toxic form of superoxide dismutase 1 protein to pathologically affected tissues in familial ALS.	Proceedings of the National Academy of Sciences of the United States of America	2012	31
22967507	6647	Weisberg SJ	Compartmentalization of superoxide dismutase 1 (SOD1G93A) aggregates determines their toxicity.	Proceedings of the National Academy of Sciences of the United States of America	2012	37
22645360	7276	Bulawa CE	Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.	Proceedings of the National Academy of Sciences of the United States of America	2012	97
18347221	7450	Spiel AO	von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes.	Circulation	2008	71
21231916	10049	Hageman J	The diverse members of the mammalian HSP70 machine show distinct chaperone-like activities.	The Biochemical journal	2011	44
22334415	10049	Harms MB	Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy.	Annals of neurology	2012	38
15801961	11093	Kokame K	FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.	British journal of haematology	2005	88
15502874	11315	Shendelman S	DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation.	PLoS biology	2004	129
15952880	11315	Cookson MR	The biochemistry of Parkinson's disease.	Annual review of biochemistry	2005	165
16227205	11315	Zhou W	DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity.	The Journal of biological chemistry	2005	93
21245577	23336	Hansen C	α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells.	The Journal of clinical investigation	2011	209
23744071	23336	Prots I	α-Synuclein oligomers impair neuronal microtubule-kinesin interplay.	The Journal of biological chemistry	2013	26
24728187	23336	Fares MB	The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.	Human molecular genetics	2014	28
25416158	23336	Harischandra DS	α-Synuclein protects against manganese neurotoxic insult during the early stages of exposure in a dopaminergic cell model of Parkinson's disease.	Toxicological sciences 	2015	17
26179554	23336	Keshavarzian A	Colonic bacterial composition in Parkinson's disease.	Movement disorders 	2015	25
18434538	23435	Johnson BS	A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity.	Proceedings of the National Academy of Sciences of the United States of America	2008	148
19383787	23435	Zhang YJ	Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity.	Proceedings of the National Academy of Sciences of the United States of America	2009	158
19465477	23435	Johnson BS	TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity.	The Journal of biological chemistry	2009	182
19515851	23435	Nonaka T	Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43.	Human molecular genetics	2009	82
19833869	23435	Wegorzewska I	TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2009	190
19959528	23435	Kabashi E	Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo.	Human molecular genetics	2010	120
20154090	23435	Hanson KA	Ubiquilin modifies TDP-43 toxicity in a Drosophila model of amyotrophic lateral sclerosis (ALS).	The Journal of biological chemistry	2010	56
20702714	23435	Xu YF	Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice.	The Journal of neuroscience 	2010	129
21209826	23435	Yang C	The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism.	PloS one	2010	42
21355045	23435	Zhang T	TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling.	Human molecular genetics	2011	36
21454603	23435	Furukawa Y	A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions.	The Journal of biological chemistry	2011	60
21454607	23435	Pesiridis GS	A "two-hit" hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43 protein linked to RNA depletion and impaired microtubule-dependent transport.	The Journal of biological chemistry	2011	41
21541367	23435	Sun Z	Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS.	PLoS biology	2011	119
21847013	23435	Gitler AD	RNA-binding proteins with prion-like domains in ALS and FTLD-U.	Prion	2011	43
22028219	23435	Jucker M	Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders.	Annals of neurology	2011	141
22029574	23435	Xu YF	Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice.	Molecular neurodegeneration	2011	44
23629963	23435	Li YR	Stress granules as crucibles of ALS pathogenesis.	The Journal of cell biology	2013	159
23831027	23435	Nonaka T	Prion-like properties of pathological TDP-43 aggregates from diseased brains.	Cell reports	2013	62
23891805	23435	Burkhardt MF	A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells.	Molecular and cellular neurosciences	2013	50
23900071	23435	Janssens J	Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders.	Human molecular genetics	2013	33
26669444	23435	Lokireddy S	cAMP-induced phosphorylation of 26S proteasomes on Rpn6/PSMD11 enhances their activity and the degradation of misfolded proteins.	Proceedings of the National Academy of Sciences of the United States of America	2015	17
27015757	23435	Ratti A	Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.	Journal of neurochemistry	2016	20
17287498	23621	Xie Z	The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation.	The Journal of neuroscience 	2007	74
19006075	23621	Xie Z	The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein level in vivo.	Annals of neurology	2008	89
19815015	23621	Hampel H	Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.	Experimental neurology	2010	41
18550655	23636	Vergarajauregui S	Autophagic dysfunction in mucolipidosis type IV patients.	Human molecular genetics	2008	57
22518844	23636	Liu XD	Transient aggregation of ubiquitinated proteins is a cytosolic unfolded protein response to inflammation and endoplasmic reticulum stress.	The Journal of biological chemistry	2012	32
22689910	23636	Schaeffer V	Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy.	Brain 	2012	57
25305202	51206	Levade M	Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.	Blood	2014	27
24942732	54205	Luth ES	Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction.	The Journal of biological chemistry	2014	24
18206732	64805	Gilard M	Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.	Journal of the American College of Cardiology	2008	102
20079528	64805	Cannon CP	Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.	Lancet	2010	50
24076493	64805	Tantry US	Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.	Journal of the American College of Cardiology	2013	57
24784220	64805	Zhang J	Agonist-bound structure of the human P2Y12 receptor.	Nature	2014	38
16437584	120892	Giasson BI	Biochemical and pathological characterization of Lrrk2.	Annals of neurology	2006	67
25556000	126393	Bakthisaran R	Small heat shock proteins: Role in cellular functions and pathology.	Biochimica et biophysica acta	2015	32
23423380	203228	Reddy K	The disease-associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures.	The Journal of biological chemistry	2013	80
25120191	203228	May S	C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration.	Acta neuropathologica	2014	51
25173361	203228	Zhang YJ	Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress.	Acta neuropathologica	2014	54
25521377	203228	Wen X	Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death.	Neuron	2014	61
25575510	203228	Tao Z	Nucleolar stress and impaired stress granule formation contribute to C9orf72 RAN translation-induced cytotoxicity.	Human molecular genetics	2015	29
